Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
Follow TECH
Bio-Techne Corp (TECH) Net margin
Bio-Techne Corp's net margin over the twelve months to 30 June 2026 was 15.0%. Over the past ten years it has ranged from 6.02% (fiscal 2025) to 31.0% (fiscal 2020); the current reading is higher than 42% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2026 | 15.0% | 8.95 |
| FY2025 | 6.02% | (8.48) |
| FY2024 | 14.5% | (10.60) |
| FY2023 | 25.1% | 0.49 |
| FY2022 | 24.6% | 9.53 |
| FY2021 | 15.1% | (15.96) |
| FY2020 | 31.0% | 17.58 |
| FY2019 | 13.5% | (6.16) |
| FY2018 | 19.6% | 6.11 |
| FY2017 | 13.5% | (7.43) |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 17.0% | 0.62 |
| Mar 2026 | 16.4% | 3.54 |
| Dec 2025 | 12.9% | (0.48) |
| Sep 2025 | 13.3% | 18.91 |
| 42 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 54.8% |
| TECH Bio-Techne Corp | 15.0% |
| CORT Corcept Therapeutics Incorporated compare | 6.53% |
| BMRN BioMarin Pharmaceutical Inc. compare | 2.14% |
| PCVX Vaxcyte, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −25.3% |
| BBIO BridgeBio Pharma, Inc. compare | −97.0% |
| IBRX ImmunityBio, Inc. compare | −598.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.45% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement